Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries

Hideki Maeda, Tatsuo Kurokawa

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Approved doses of a number of drugs in Japan are known to be different from those in the United States (US) and the European Union (EU), and doses are often set lower for the Japanese than for the western people. Similarly, some oncology drugs also have lower dose approved for the Japanese than for the western people. A total of 40 oncology drugs were approved as new molecular entities in Japan between 2001 and 2013. Of the 40 drugs, 21 were molecularly targeted drugs and 13 were cytotoxic drugs. Five (12.5 %) of the 40 drugs had different approved dose from that in the US and the EU. Of the 13 cytotoxic drugs, four drugs (30.8 %) differed in approved dose, while all the molecularly targeted drugs (21 of 21 drugs) had the same approved dose. We compared the maximum tolerated dose (MTD) of the 21 molecularly targeted drugs in the Japanese with that in the western people and found that the MTD was determined lower in the Japanese than that in the western people (two drugs), was not different (10 drugs), and MTD was not determined in the Japanese and incommensurable because of the different dose range tested in Japan (nine drugs). All the molecularly targeted drugs are the same in approved doses and few molecularly targeted drugs differ in MTD between Japan and the Western countries.

Original languageEnglish
Pages (from-to)661-669
Number of pages9
JournalInvestigational New Drugs
Volume32
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Maximum Tolerated Dose
Japan
Pharmaceutical Preparations
European Union

Keywords

  • Anticancer drug
  • Approval dose
  • Ethnic difference
  • Japan
  • Maximum tolerated dose
  • Oncology

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology
  • Medicine(all)

Cite this

Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries. / Maeda, Hideki; Kurokawa, Tatsuo.

In: Investigational New Drugs, Vol. 32, No. 4, 2014, p. 661-669.

Research output: Contribution to journalArticle

@article{415626b74af94f26a078a2336dc7e19a,
title = "Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries",
abstract = "Approved doses of a number of drugs in Japan are known to be different from those in the United States (US) and the European Union (EU), and doses are often set lower for the Japanese than for the western people. Similarly, some oncology drugs also have lower dose approved for the Japanese than for the western people. A total of 40 oncology drugs were approved as new molecular entities in Japan between 2001 and 2013. Of the 40 drugs, 21 were molecularly targeted drugs and 13 were cytotoxic drugs. Five (12.5 {\%}) of the 40 drugs had different approved dose from that in the US and the EU. Of the 13 cytotoxic drugs, four drugs (30.8 {\%}) differed in approved dose, while all the molecularly targeted drugs (21 of 21 drugs) had the same approved dose. We compared the maximum tolerated dose (MTD) of the 21 molecularly targeted drugs in the Japanese with that in the western people and found that the MTD was determined lower in the Japanese than that in the western people (two drugs), was not different (10 drugs), and MTD was not determined in the Japanese and incommensurable because of the different dose range tested in Japan (nine drugs). All the molecularly targeted drugs are the same in approved doses and few molecularly targeted drugs differ in MTD between Japan and the Western countries.",
keywords = "Anticancer drug, Approval dose, Ethnic difference, Japan, Maximum tolerated dose, Oncology",
author = "Hideki Maeda and Tatsuo Kurokawa",
year = "2014",
doi = "10.1007/s10637-014-0080-y",
language = "English",
volume = "32",
pages = "661--669",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries

AU - Maeda, Hideki

AU - Kurokawa, Tatsuo

PY - 2014

Y1 - 2014

N2 - Approved doses of a number of drugs in Japan are known to be different from those in the United States (US) and the European Union (EU), and doses are often set lower for the Japanese than for the western people. Similarly, some oncology drugs also have lower dose approved for the Japanese than for the western people. A total of 40 oncology drugs were approved as new molecular entities in Japan between 2001 and 2013. Of the 40 drugs, 21 were molecularly targeted drugs and 13 were cytotoxic drugs. Five (12.5 %) of the 40 drugs had different approved dose from that in the US and the EU. Of the 13 cytotoxic drugs, four drugs (30.8 %) differed in approved dose, while all the molecularly targeted drugs (21 of 21 drugs) had the same approved dose. We compared the maximum tolerated dose (MTD) of the 21 molecularly targeted drugs in the Japanese with that in the western people and found that the MTD was determined lower in the Japanese than that in the western people (two drugs), was not different (10 drugs), and MTD was not determined in the Japanese and incommensurable because of the different dose range tested in Japan (nine drugs). All the molecularly targeted drugs are the same in approved doses and few molecularly targeted drugs differ in MTD between Japan and the Western countries.

AB - Approved doses of a number of drugs in Japan are known to be different from those in the United States (US) and the European Union (EU), and doses are often set lower for the Japanese than for the western people. Similarly, some oncology drugs also have lower dose approved for the Japanese than for the western people. A total of 40 oncology drugs were approved as new molecular entities in Japan between 2001 and 2013. Of the 40 drugs, 21 were molecularly targeted drugs and 13 were cytotoxic drugs. Five (12.5 %) of the 40 drugs had different approved dose from that in the US and the EU. Of the 13 cytotoxic drugs, four drugs (30.8 %) differed in approved dose, while all the molecularly targeted drugs (21 of 21 drugs) had the same approved dose. We compared the maximum tolerated dose (MTD) of the 21 molecularly targeted drugs in the Japanese with that in the western people and found that the MTD was determined lower in the Japanese than that in the western people (two drugs), was not different (10 drugs), and MTD was not determined in the Japanese and incommensurable because of the different dose range tested in Japan (nine drugs). All the molecularly targeted drugs are the same in approved doses and few molecularly targeted drugs differ in MTD between Japan and the Western countries.

KW - Anticancer drug

KW - Approval dose

KW - Ethnic difference

KW - Japan

KW - Maximum tolerated dose

KW - Oncology

UR - http://www.scopus.com/inward/record.url?scp=84904537766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904537766&partnerID=8YFLogxK

U2 - 10.1007/s10637-014-0080-y

DO - 10.1007/s10637-014-0080-y

M3 - Article

VL - 32

SP - 661

EP - 669

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -